Gossamer Bio Inc. (NASDAQ:GOSS) is one of the penny stocks with the potential to rise 1000 percent.
Gossamer Bio remained in focus in March 2026 after its late-February Phase 3 PROSERA study of seralutinib in pulmonary arterial hypertension missed its primary endpoint, though the company said it planned to meet with the U.S. Food and Drug Administration to discuss a potential path forward and paused enrollment in the SERANATA study while it reviewed the data.
Even after cutting their price targets, both Oppenheimer and H.C. Wainwright kept bullish ratings on the stock. On March 5, Oppenheimer maintained its Outperform rating and lowered its target to $3 from $12. On March 6, H.C. Wainwright maintained its Buy rating and cut its target to $5 from $10. Based on Gossamer Bio’s recent share price of about $0.37, Oppenheimer’s target still implied upside of more than 700%, while H.C. Wainwright’s target implied upside of more than 1,200%.
Public summaries of the H.C. Wainwright update noted that analyst Patrick Trucchio reduced the estimated probability of success for seralutinib in PAH to 50% from 70%. Even so, later reporting on the firm’s view said the data still “demonstrate evidence of clinical activity,” particularly in heavily pretreated patients, and that “a path forward may yet emerge,” although regulatory and capital uncertainty would likely remain an overhang.
Gossamer Bio, Inc. (NASDAQ:GOSS) is a clinical-stage biopharmaceutical company developing therapies for pulmonary hypertension and other serious diseases.
While we acknowledge the potential of GOSS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.
Disclosure: None. Follow Insider Monkey on Google News.
















